Drugs / bedoradrine
bedoradrine
also known as
MN-221 · Bedoradrina · bedoradrine sulfate · Bedoradrine sulphate · KUR-1246 · KUR-1246 FREE BASE · KUR-1246 MONOSULPHATE · MN-221 FREE BASE
Small molecule targets ADRB2 via activation
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01551316 | Mar → May 2012 | chronic obstructive pulmonary disease | MediciNova | Completed | No outcome recorded |
| Phase 1 | NCT01013142 | Nov 2009 → Mar 2010 | chronic obstructive pulmonary disease | MediciNova | Completed | No outcome recorded |
| Phase 23 trials · 1 missed | ||||||
| Phase 2 | NCT00838591 | Mar 2009 → Mar 2012 | asthma | MediciNova | Completed | Missed primary |
| Phase 2 | NCT00683449 | Jun 2008 → Mar 2009 | status asthmaticus | MediciNova | Terminated | No outcome recorded |
| Phase 2 | NCT00679263 | Feb → Jul 2008 | asthma | MediciNova | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2018-04-23 | MediciNova | Regulatory MediciNova Receives Notice of Allowance for New Patent Covering MN-221 (bedoradrine) for the Treatment of Irritable Bowel Syndrome in Japan medicinova.com ↗ |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2018-04-23 | MediciNova | MediciNova Receives Notice of Allowance for New Patent Covering MN-221 (bedoradrine) for the Treatment of Irritable Bowel Syndrome in Japan medicinova.com ↗ |
| 2004-02-25 | Kissei Pharmaceutical Co., Ltd. | 新規切迫早産治療剤「KUR-1246」のメディシノバ社への技術導出契約締結のお知らせ kissei.co.jp ↗ |
| 2001-01-22 | Kissei Pharmaceutical Co., Ltd. | 切迫早産治療薬「KUR-1246」の共同開発契約締結のお知らせ kissei.co.jp ↗ |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bedoradrine | “intravenous bedoradrine (MN-221)” PMID 26324315 ↗ Aug 2015 |
| Known as | Bedoradrina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2111083 ↗ |
| Known as | bedoradrine sulfate | “Evaluation of bedoradrine sulfate (MN-221), a novel, highly selective beta2-adrenergic receptor agonist for the treatment of asthma via intravenous infusion.” PMID 23094708 ↗ Oct 2012 |
| Known as | Bedoradrine sulphate | ChEMBL registry synonym — accepted as the source's own label CHEMBL2111083 ↗ |
| Known as | KUR-1246 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2111083 ↗ |
| Known as | KUR-1246 FREE BASE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2111083 ↗ |
| Known as | KUR-1246 MONOSULPHATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2111083 ↗ |
| Known as | MN-221 | “IV infusion of MN-221 16 mcg/min for 15 min; total dose of 240 mcg” NCT00683449 ↗ |
| Known as | MN-221 FREE BASE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2111083 ↗ |
| Action | Activate | “Beta-2 adrenergic receptor agonist” CHEMBL2111083 ↗1“beta2-adrenergic receptor agonist” PMID 23094708 ↗ Oct 2012 |
| Modality | Small molecule | — CHEMBL2111083 ↗ |
| Route | Intravenous | “administered via intravenous (IV) infusion” PMID 23094708 ↗ Oct 2012 |
| Target | ADRB2 | “Beta-2 adrenergic receptor agonist” CHEMBL2111083 ↗ |